Silencing of STAT4 Protects Against Autoimmune Myocarditis by Regulating Th1/Th2 Immune Response via Inactivation of the NF-κB Pathway in Rats
- 54 Downloads
Signal transducer and activator of transcription 4 (STAT4) has been implicated in the progression of myocarditis. The aim of the current study was to investigate the role by which STAT4 influences autoimmune myocarditis in an attempt to identify a theoretical therapeutic perspective for the condition. After successful establishment of an autoimmune myocarditis rat model, the expression patterns of STAT4, NF-κB pathway–related genes, Th1 inflammatory cytokines (IFN-γ and IL-2), and Th2 inflammatory cytokines (IL-6 and IL-10) were subsequently determined. The rats with autoimmune myocarditis were treated with oe-STAT4 or sh-STAT4 lentiviral vectors to evaluate the role of STAT4 in autoimmune myocarditis, or administrated with 1 mL 10 μmol/L of BAY11-7082 (the NF-κB pathway inhibitor) via tail vein to investigate the effect of the NF-κB pathway on autoimmune myocarditis. Finally, cell apoptosis was evaluated. The serum levels of IFN-γ and IL-2, extent of IκBα and P65 phosphorylation, and the expression of STAT4 were elevated, while the serum levels of IL-6 and IL-10 as well as the expression of IκBα were reduced among the rats with autoimmune myocarditis, which was accompanied by an increase in the apoptotic cells. More importantly, the silencing of STAT4 or the inhibition of the NF-κB pathway was detected to result in a decrease in the serum levels of IFN-γ and IL-2 and an elevation of the serum levels of IL-6 and IL-10, and inhibited myocardial cell apoptosis in rats with autoimmune myocarditis. Moreover, STAT4 silencing was also observed to decrease the extent of IκBα and P65 phosphorylation while acting to elevate the expression of IκBα. Taken together, silencing of STAT4 could hinder the progression of autoimmune myocarditis by balancing the expression of Th1/Th2 inflammatory cytokines via the NF-κB pathway, which may provide a novel target for experimental autoimmune myocarditis (EAM) treatment.
Key Wordssignal transducer and activator of transcription 4 NF-κB pathway autoimmune myocarditis Th1/2 cytokines
We acknowledge and appreciate our colleagues for their valuable efforts and comments on this paper.
Compliance with Ethical Standards
The authors declare that they have no conflict of interest.
- 1.Wu, B., H. Ni, J. Li, X. Zhuang, J. Zhang, Z. Qi, Q. Chen, Z. Wen, H. Shi, X. Luo, and B. Jin. 2017. The impact of circulating mitochondrial DNA on cardiomyocyte apoptosis and myocardial injury after TLR4 activation in experimental autoimmune myocarditis. Cellular Physiology and Biochemistry 42 (2): 713–728.CrossRefGoogle Scholar
- 3.Steinl, D. C., L. Xu, E. Khanicheh, E. Ellertsdottir, A. Ochoa-Espinosa, M. Mitterhuber, K. Glatz, G. M. Kuster, B. A. Kaufmann 2016. Noninvasive contrast-enhanced ultrasound molecular imaging detects myocardial inflammatory response in autoimmune myocarditis. Circulation. Cardiovascular Imaging 9(8).Google Scholar
- 4.Nana-Leventaki, E., M. Nana, N. Poulianitis, D. Sampaziotis, D. Perrea, D. Sanoudou, et al. 2018. Cardiosphere-derived cells attenuate inflammation, preserve systolic function, and prevent adverse remodeling in rat hearts with experimental autoimmune myocarditis. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/1074248418784287.
- 7.Karuppagounder, V., A. Bajpai, S. Meng, S. Arumugam, R. Sreedhar, V.V. Giridharan, A. Guha, A. Bhimaraj, K.A. Youker, S.S. Palaniyandi, H. Karmouty-Quintana, F. Kamal, K.L. Spiller, K. Watanabe, and R.A. Thandavarayan. 2018. Small molecule disruption of G protein betagamma subunit signaling reprograms human macrophage phenotype and prevents autoimmune myocarditis in rats. PLoS One 13 (7): e0200697.CrossRefGoogle Scholar
- 8.Varikuti, S., S. Oghumu, G. Natarajan, J. Kimble, R.H. Sperling, E. Moretti, M.H. Kaplan, and A.R. Satoskar. 2016. STAT4 is required for the generation of Th1 and Th2, but not Th17 immune responses during monophosphoryl lipid A adjuvant activity. International Immunology 28 (11): 565–570.CrossRefGoogle Scholar
- 10.Massilamany, C., A. Gangaplara, R.H. Basavalingappa, R.A. Rajasekaran, V. Khalilzad-Sharghi, Z. Han, S. Othman, D. Steffen, and J. Reddy. 2016. Localization of CD8 T cell epitope within cardiac myosin heavy chain-alpha334-352 that induces autoimmune myocarditis in A/J mice. International Journal of Cardiology 202: 311–321.CrossRefGoogle Scholar
- 11.Shi, Y., H. Pan, H.Z. Zhang, X.Y. Zhao, J. Jin, and H.Y. Wang. 2017. Lipoxin A4 mitigates experimental autoimmune myocarditis by regulating inflammatory response, NF-kappaB and PI3K/Akt signaling pathway in mice. European Review for Medical and Pharmacological Sciences 21 (8): 1850–1859.Google Scholar
- 17.Okuda, K., H.Y. Fu, T. Matsuzaki, R. Araki, S. Tsuchida, P.V. Thanikachalam, T. Fukuta, T. Asai, M. Yamato, S. Sanada, H. Asanuma, Y. Asano, M. Asakura, H. Hanawa, H. Hao, N. Oku, S. Takashima, M. Kitakaze, Y. Sakata, and T. Minamino. 2016. Targeted therapy for acute autoimmune myocarditis with nano-sized liposomal FK506 in rats. PLoS One 11 (8): e0160944.CrossRefGoogle Scholar
- 18.Tajiri, K., N. Shimojo, S. Sakai, T. Machino-Ohtsuka, K. Imanaka-Yoshida, M. Hiroe, Y. Tsujimura, T. Kimura, A. Sato, Y. Yasutomi, and K. Aonuma. 2013. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovascular Drugs and Therapy 27 (5): 413–424.CrossRefGoogle Scholar
- 22.Watanabe, R., R.W. Azuma, J. Suzuki, M. Ogawa, A. Itai, Y. Hirata, I. Komuro, and M. Isobe. 2013. Inhibition of NF-kappaB activation by a novel IKK inhibitor reduces the severity of experimental autoimmune myocarditis via suppression of T-cell activation. American Journal of Physiology. Heart and Circulatory Physiology 305 (12): H1761–H1771.CrossRefGoogle Scholar
- 24.Pierer, M., J. Rethage, R. Seibl, R. Lauener, F. Brentano, U. Wagner, H. Hantzschel, B.A. Michel, R.E. Gay, S. Gay, and D. Kyburz. 2004. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. Journal of Immunology 172 (2): 1256–1265.CrossRefGoogle Scholar